Today’s Research Reports on Stocks to Watch: Teva and Therapix

NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Shares of Therapix were popping on Monday after positive trial results about the company’s proprietary cannabinoid product platform THX-IIO fell upon the eyes of investors. Teva Pharmaceutical Industries also saw a slight gain as the company’s chairman discussed potential tariffs and their possible effects on Bloomberg and after the company said it would be closing a plant in Israel.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Limited
https://rdinvesting.com/news/?ticker=TEVA

Therapix Biosciences Ltd.
https://rdinvesting.com/news/?ticker=TRPX

Teva Pharmaceutical Industries Limited shares closed up 1.48% on Monday with nearly 8.5 million shares traded. The Israeli pharma giant’s chairman Sol Barer discussed the effect that potential Chinese tariffs could have on the biotech industry with Bloomberg’s Vonnie Quinn and Shery Ahn yesterday. According to Barer, the tariffs “will not have a major effect.” Teva also announced yesterday that it would close a plant in Ashdod in Israel next March after not being able to find a buyer for it. The company said to Reuters, “The Teva Ashdod plant is part of the reorganization process being carried out in Israel and around the world in order to reduce the cost base due to the heavy debt the company faces and the complex business circumstances it is dealing with. Teva has examined the possibility of selling the plant in recent months but unfortunately no suitable buyer was found.”

Access RDI’s Teva Pharmaceutical Industries Limited Research Report at:
https://rdinvesting.com/news/?ticker=TEVA

Therapix Biosciences Ltd. shares were soaring on Monday to close up 15.58% on about 6.1 million shares traded. This was explosive compared to the stock’s average trading volume of just around 25,000 shares. Shares of the specialty pharmaceutical company that is developing unique cannabinoid technologies for treatment of central nervous system disorders, exploded after the company reported positive trial results for the treatment of Tourette syndrome. Shares had skyrocketed over 30% in pre-market trading yesterday after Wall Street saw the news. The company’s proprietary cannabinoid product platform THX-IIO was found to significantly improve symptoms of the condition over time. Chief Technology Officer Adi Zuloff-Shani remarked, “These results are of particular interest as the pharmacology of THX-110 appears to be distinct from existing medications for TS and may offer a unique option for treating these patients.” It was a nice climb for the stock which, as per Friday’s close, has dropped around 30% in the last twelve months.

Access RDI’s Therapix Biosciences Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=TRPX

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Therapix Biosciences Ltd. (NASDAQ: TRPX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

SOURCE: RDInvesting.com

ReleaseID: 495644